COVID-19 outcomes for patients on immunosuppressive drugs on par with non- immunosuppressed patients

January 07, 2021

People taking immunosuppressive drugs to prevent organ transplant rejection or to treat inflammatory or autoimmune diseases do not fare worse than others on average when they are hospitalized with COVID-19, according to a study from researchers at the Johns Hopkins Bloomberg School of Public Health.

Estimates suggest that there are approximately 10 million immunocompromised people in the U.S. alone. Suppression of the immune system has been considered a potentially major risk factor for severe and fatal COVID-19 because it could allow the SARS-CoV-2 virus to spread unchecked in the body. At the same time, there have been anecdotal reports of immunosuppressed people who experienced only mild COVID-19 or even no symptoms at all--suggesting that immunosuppressive drugs might have a protective effect by preventing the inflammatory storm sometimes associated with severe COVID-19.

For their study, the researchers analyzed the anonymized records of 2,121 hospitalized COVID-19 patients seen at the Johns Hopkins Medicine medical system in Baltimore, MD, and Washington, D.C., from March 4 to August 29, 2020. They found that the COVID-19 patients who were immunosuppressed prior to their COVID-19 hospitalization did not, on average, have worse COVID-19 outcomes--such as longer length of stay in the hospital, death in hospital, or use of a ventilator--compared to their counterparts who were not immunosuppressed.

The study was published January 5 in Clinical Infectious Diseases.

"The COVID pandemic has released a wave of scientific investigations that examine who fares better and who fares worse with this new virus. We examined one important group of individuals, those on chronic immunosuppressive medicines such as people with a history of organ transplantation or rheumatologic disease and found some good news," says senior author G. Caleb Alexander, MD, a professor in the Bloomberg School's Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health and a practicing internist.

"There has been concern that immunosuppression might be an important risk factor for severe COVID-19, but reassuringly we found no sign of that," says study first author Kayte Andersen, a PhD candidate in the Bloomberg School's Department of Epidemiology.

To date, there have been 83 million COVID-19 cases confirmed around the world, and the Northern Hemisphere's recent shift to cold weather has brought the largest surge in new cases. Many health care systems are struggling to cope with this surge and are trying to allocate limited resources. Knowing which incoming patients are more likely to progress to severe COVID-19 helps them do that. But whether patients who are "immunocompromised" due to immune-suppressing drug treatment belong in the highest risk category has been a mystery.

The Johns Hopkins researchers found that 108, or about 5 percent, of the total COVID-19 cases hospitalized in the Baltimore/Washington Johns Hopkins medical network during the study period could be classified as immunosuppressed because they were taking an anti-inflammatory drug such as prednisone or an anti-rejection drug such as tacrolimus after organ transplant.

These results were obtained after using statistical methods to account for differences between the groups in factors such as age, sex, and non-COVID-19 disease burden that might have skewed the analysis. But even the researchers' raw, unadjusted analysis found no statistical association between worse COVID-19 outcomes and immunosuppression status.

The researchers are now following up with an analysis of a much larger set of data of nationwide COVID-19 cases, which should allow for more precise estimates, potentially including findings of different risks for different types of immunosuppression medications. However, they note, the findings in this smaller study suggest at the very least that immunosuppression does not appear to be associated with a major worsening of COVID-19 outcomes.

"At this point, there is no indication that people taking immunosuppressive drugs for other diagnosed conditions should be concerned that their medication increases their risk for severe COVID-19," Andersen says.
-end-
"Association Between Chronic Use of Immunosuppressive Drugs and Clinical Outcomes from COVID-19 Hospitalization: A Retrospective Cohort Study in a Large U.S. Health System" was written by Kathleen Andersen, Hemalkumar Mehta, Natasha Palamuttam, Daniel Ford, Brian Garibaldi, Paul Auwaerter, Jodi Segal, and G. Caleb Alexander.

Johns Hopkins University Bloomberg School of Public Health

Related Public Health Articles from Brightsurf:

COVID-19 and the decolonization of Indigenous public health
Indigenous self-determination, leadership and knowledge have helped protect Indigenous communities in Canada during the coronavirus disease 2019 (COVID-19) pandemic, and these principles should be incorporated into public health in future, argue the authors of a commentary in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.200852.

Public health consequences of policing homelessness
In a new study examining homelessness, researchers find that policy such a lifestyle has massive public health implications, making sleeping on the street even MORE unhealthy.

Electronic health information exchange improves public health disease reporting
Disease tracking is an important area of focus for health departments in the midst of the COVID-19 pandemic.

Pandemic likely to cause long-term health problems, Yale School of Public Health finds
The coronavirus pandemic's life-altering effects are likely to result in lasting physical and mental health consequences for many people--particularly those from vulnerable populations--a new study led by the Yale School of Public Health finds.

The Lancet Public Health: US modelling study estimates impact of school closures for COVID-19 on US health-care workforce and associated mortality
US policymakers considering physical distancing measures to slow the spread of COVID-19 face a difficult trade-off between closing schools to reduce transmission and new cases, and potential health-care worker absenteeism due to additional childcare needs that could ultimately increase mortality from COVID-19, according to new modelling research published in The Lancet Public Health journal.

The Lancet Public Health: Access to identification documents reflecting gender identity may improve trans mental health
Results from a survey of over 20,000 American trans adults suggest that having access to identification documents which reflect their identified gender helps to improve their mental health and may reduce suicidal thoughts, according to a study published in The Lancet Public Health journal.

The Lancet Public Health: Study estimates mental health impact of welfare reform, Universal Credit, in Great Britain
The 2013 Universal Credit welfare reform appears to have led to an increase in the prevalence of psychological distress among unemployed recipients, according to a nationally representative study following more than 52,000 working-age individuals from England, Wales, and Scotland over nine years between 2009-2018, published as part of an issue of The Lancet Public Health journal on income and health.

BU researchers: Pornography is not a 'public health crisis'
Researchers from the Boston University School of Public Health (BUSPH) have written an editorial in the American Journal of Public Health special February issue arguing against the claim that pornography is a public health crisis, and explaining why such a claim actually endangers the health of the public.

The Lancet Public Health: Ageism linked to poorer health in older people in England
Ageism may be linked with poorer health in older people in England, according to an observational study of over 7,500 people aged over 50 published in The Lancet Public Health journal.

Study: Public transportation use linked to better public health
Promoting robust public transportation systems may come with a bonus for public health -- lower obesity rates.

Read More: Public Health News and Public Health Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.